Drug Design: Functional groups / Pharmacological Activity Structure ...
Transcript of Drug Design: Functional groups / Pharmacological Activity Structure ...
![Page 1: Drug Design: Functional groups / Pharmacological Activity Structure ...](https://reader031.fdocuments.us/reader031/viewer/2022030319/584999d91a28aba93a915a85/html5/thumbnails/1.jpg)
Drug Design:Functional groups / Pharmacological Activity
Structure - Mechanism of action (Interaction with target)
Structure - Physiochemical properties (Bioavailability etc)• Acid / base properties• Water solubility• Partition coefficient• (Crystal structure)• Stereochemistry
ADME
Absorbtion. Distribution, Metabolism, Excretion(ADMET, ADMEtox)
![Page 2: Drug Design: Functional groups / Pharmacological Activity Structure ...](https://reader031.fdocuments.us/reader031/viewer/2022030319/584999d91a28aba93a915a85/html5/thumbnails/2.jpg)
Structure - Mechanism of action
NO
O
O H
ca. 5Å
Acetylcholin (Neurotransmittor)
NO
O
H2N
Carbacholin
N
NH N
NMe
HO
O
Acetylcholin Agonists
Nicotine Pilocarpine
Protonated av phys. pH (pH≈7.4)
Acetylcholin Antagonists
N
OO
OH
Atropin
OO
N
OH
Cyclopentolat
MeO
O
HO
OOH
OMe
NH
Me
NMe
Me
TubocurarinCNS
Effektor celleReseptor
Synapse
Acetylkolin
Noradrenalin
Det somatiske nervesystem Det autonome nervesystem
CNS CNS
Det sympatiskenervesystem
Det parasympatiskenervesystem
ganglion
![Page 3: Drug Design: Functional groups / Pharmacological Activity Structure ...](https://reader031.fdocuments.us/reader031/viewer/2022030319/584999d91a28aba93a915a85/html5/thumbnails/3.jpg)
Structure - Mechanism of actionSAR: Structure Activity Relationships
Acetylcholine agonists: Small N-quartenary compds.Acetylcholine antagonists: Larger N-quartenary compds.
NCO2Me
O
OCocaine
O
O
N
NH2
Procaine (1905)
NH
N
Lidocaine/Xylocaine(1946)
O
Acid labile ester
HydrophilicAminogroup(can be protonated)
Spacer-Cn-X-X: -CO2- -CONH- -NHCO-
Lipophilic(Aryl)
![Page 4: Drug Design: Functional groups / Pharmacological Activity Structure ...](https://reader031.fdocuments.us/reader031/viewer/2022030319/584999d91a28aba93a915a85/html5/thumbnails/4.jpg)
Active compound identifiedTarget?
Target identifiedLigand?
![Page 5: Drug Design: Functional groups / Pharmacological Activity Structure ...](https://reader031.fdocuments.us/reader031/viewer/2022030319/584999d91a28aba93a915a85/html5/thumbnails/5.jpg)
Structure - Physiochemical properties
• Acid / base properties• Water solubility• Partition coefficient• (Crystal structure)• Stereochemistry
Human body: ca 75% waterpH blood ca 7.4 (physiolog. pH)pH stomach 1 - 3.5pH duodenum ca. 4pH urine ca. 6
Identification of acidic / basic functional groupspKa determines degree of ionization different places in the body
![Page 6: Drug Design: Functional groups / Pharmacological Activity Structure ...](https://reader031.fdocuments.us/reader031/viewer/2022030319/584999d91a28aba93a915a85/html5/thumbnails/6.jpg)
NO
O
O H
ca. 5Å
Acetylcholin (Neurotransmittor)
Acetylcholin Antagonists Possible atropine analogs?
OO
N
OH
Cyclopentolat
OO
N
OHOO
N
OHOO
N
OH
O
Cyclopentolate - tertiary amine, pKa ca. 10
[acid form]
[base form]
At pH 7.4
10 = 7.4 + log log[acid form]
[base form]= 2.6
[acid form]
[base form]= 398; 99.75% acid form
OO
N
OHH = active form
OO
N
OHH
acid form
+ H20 OO
N
OH
baseform
+ H3O
pKa = pH + log[acid form]
[base form]Henderson Hasselbach
pH=pKa; [acid]= [base]pH<pKa; acid form dominatespH>pKa; basic form dominates
![Page 7: Drug Design: Functional groups / Pharmacological Activity Structure ...](https://reader031.fdocuments.us/reader031/viewer/2022030319/584999d91a28aba93a915a85/html5/thumbnails/7.jpg)
Antibacterial sulfonamides
Old compound
NH2SO
OH2N
Acid form - neutralLow watersol. - crystals - Kidney damage
[acid form]
[base form]
At pH 6 (urine)
10.4 = 6 + log[acid form]
[base form]≈ 25000
Modern compound
ArSO
OHN
Sulfametoksasol pKa 6.1
ArSO
ON
- H+
ArSO
ON ArS
O
ON
NO
NO
NO NO
ArSO
ON
NO
At pH 6 (urine)
[acid form]
[base form]≈ 1
base form, ionic, water sol.
![Page 8: Drug Design: Functional groups / Pharmacological Activity Structure ...](https://reader031.fdocuments.us/reader031/viewer/2022030319/584999d91a28aba93a915a85/html5/thumbnails/8.jpg)
Structure - Physiochemical properties• Acid / base properties• Water solubility• Partition coefficient• (Crystal structure)• Stereochemistry
Ionisation -permanent charge -acid / base properties
Hydrogen bonds
Ion - dipole bonds
HN HRH
Acidic form of amines
HO
Hδ -
δ +
δ +
R
O
O
Basic form of carboxylic acid(carboxylate)
HOHδ +
δ + δ -
Intramoleculare interact. reduce water sol.
RCO2
NH3
Strong intramolec interact.
OH H
OHH
Salts between weak organic acids and weak organic bases does not dissolve well in water
![Page 9: Drug Design: Functional groups / Pharmacological Activity Structure ...](https://reader031.fdocuments.us/reader031/viewer/2022030319/584999d91a28aba93a915a85/html5/thumbnails/9.jpg)
The more H-bonds possible - the more water sol.
RO
HAlchohol
O
HH
H
OH
OH
H
3 H-Bonds
OAldehyde / ketoneHHOH
OH
2 H-Bonds
R R'
OEsterHHOH
OH
3 H-Bonds
R OR
HO
H
Primary amine 3 H-BondsR NH
H
O
O
HO
H
H
H
HH
Secondary amine 2 H-BondsR NR'
H O
HO
H
H
H
Secondary amine 1 H-BondsR NR'
R''
HO
H
![Page 10: Drug Design: Functional groups / Pharmacological Activity Structure ...](https://reader031.fdocuments.us/reader031/viewer/2022030319/584999d91a28aba93a915a85/html5/thumbnails/10.jpg)
Prediction of water solubility - Empirical
Water solubilization of functional groupsFunctional group Monofunctional comp. Polyfunctional
comp.
Alchohol 5 – 6 carbons 3 – 4 carbons
Phenol 6 – 7 3 – 4
Ether 4 – 5 2
Aldehyde 4 – 5 2
Ketone 5 – 6 2
Amine 6 – 7 3
Carboxylic acid 5 – 6 3
Ester 6 3
Amide 6 2 - 3
Ex. monofuctional comp.methanol - pentanol/hexanol are solubile
Charge: 1 charge - 20-30 C
N
TerbinafineAntifungal agent
21 C-atom, tertiary amine solubilize 6 - 7 C atoms
Insolubile (neutral form)
Corresponding acid (cationic) solubile
(solubile: >10 mg/mL)
![Page 11: Drug Design: Functional groups / Pharmacological Activity Structure ...](https://reader031.fdocuments.us/reader031/viewer/2022030319/584999d91a28aba93a915a85/html5/thumbnails/11.jpg)
Water solubilization of functional groups
Functional group Monofunctional comp. Polyfunctional
comp.
Alchohol 5 – 6 carbons 3 – 4 carbons
Phenol 6 – 7 3 – 4
Ether 4 – 5 2
Aldehyde 4 – 5 2
Ketone 5 – 6 2
Amine 6 – 7 3
Carboxylic acid 5 – 6 3
Ester 6 3
Amide 6 2 - 3
Ex. polyfunctional comp.
Charge: 1 charge - 20-30 C
O
O
NH
OH
BetaxololBetablokker
18 C-atomer
Ether: 2
Ether: 2
Alchohol: 3-4
Amine 2
Tot: 9 - 10
(not solubile)
![Page 12: Drug Design: Functional groups / Pharmacological Activity Structure ...](https://reader031.fdocuments.us/reader031/viewer/2022030319/584999d91a28aba93a915a85/html5/thumbnails/12.jpg)
logP
Experimental: MlogP or logPmeas
P: Partition coefficient between n-octanol and water
Fragment π-value
C (aliphatic +0.5
Phenyl +2.0
-Cl +0.5
-ONO2 +0.2
-S- 0.0
O=C-O- (carboxyl) -0.7
O=C-N- (amide) -0.7
-O- (hydroxyl, ether) -1.0
N (amine) -1.0
-NO2 (aliphat.) -0.85
-NO2 (aromat.) -0.28
O
O
NH
OH
BetaxololBetablokker
12 x C aliphat: +6.0
Ph: +2.0
3 x O: -3.0
N: -1.0
logP +4.0
ClogP (SciFinder): 2.69
π-value: hydrophilic - lipophilic value
logP ∝ Rt (HPLC, TLC reverse phase)
Structure - Physiochemical properties• Acid / base properties• Water solubility• Partition coefficient• (Crystal structure)• Stereochemistry
Calcd: ClogP
![Page 13: Drug Design: Functional groups / Pharmacological Activity Structure ...](https://reader031.fdocuments.us/reader031/viewer/2022030319/584999d91a28aba93a915a85/html5/thumbnails/13.jpg)
Absorbtion of Bioactive Compounds
Absorbtion from GI tract
StomachpH 1-3
DuodenumpH 5-7
Jejunum
IleumpH 7- 8
Small intestine
+ digestive enzymes
Drug
GI-tractBlood
Membrane
Acidic / Enzymatic break down
Often rate limiting
Binding to biomolecules
![Page 14: Drug Design: Functional groups / Pharmacological Activity Structure ...](https://reader031.fdocuments.us/reader031/viewer/2022030319/584999d91a28aba93a915a85/html5/thumbnails/14.jpg)
Most drugs: Passive diffusion
StomachpH 1 - 3
BloodLipophilic Membrane
R-H R-H
R-CO2H R-CO2H
R-NH3
Amount un ionized drug
pKa pH
pKa = pH + log[acid form]
[base form]Henderson Hasselbach
Low lipophilicity unionized form - low absorbtion
logP - P: Partition coefficient between n-octanol and water Water phase - extracellular fluid
Lipophilic phase - cell membrane
![Page 15: Drug Design: Functional groups / Pharmacological Activity Structure ...](https://reader031.fdocuments.us/reader031/viewer/2022030319/584999d91a28aba93a915a85/html5/thumbnails/15.jpg)
Crossing the membrane
High conc.
Low conc.Chanel protein
Passive transport / diffusion
Rate ∝ Conc. absortion site (1. order kinetics)% Drug absorbed ∝ lipophilicity
Size of moleculeCertain ionic compounds may go thru as ion-pair
![Page 16: Drug Design: Functional groups / Pharmacological Activity Structure ...](https://reader031.fdocuments.us/reader031/viewer/2022030319/584999d91a28aba93a915a85/html5/thumbnails/16.jpg)
Active transport / Carrier mediated transport•Less common•Structural recemblanse with for instance nutritional compound•Transport against conc. gradient•Mechanism saturated at high conc.•Competition for carrier molecules, compounds with structural resemblance
Energy
![Page 17: Drug Design: Functional groups / Pharmacological Activity Structure ...](https://reader031.fdocuments.us/reader031/viewer/2022030319/584999d91a28aba93a915a85/html5/thumbnails/17.jpg)
The Lipinski "Rule of Five"
states that compounds are likely to have good absorption and permeation in biological systems and are more likely to be successful drug candidates if they meet the following criteria:
five or fewer hydrogen-bond donors
ten (2 x 5) or fewer hydrogen-bond acceptors
molecular weight less than or equal to 500
calculated logP less than or equal to 5
*Compound classes that are substrates for biological transporters are exceptions to the rule.
Not too polar
Not too big
Not too hydrophobic
![Page 18: Drug Design: Functional groups / Pharmacological Activity Structure ...](https://reader031.fdocuments.us/reader031/viewer/2022030319/584999d91a28aba93a915a85/html5/thumbnails/18.jpg)
Biomolecules (reseptors, enzymes): Asymmetric Enantiomers may behave differently:•Absorbtion (membrane selectivity)•Metabolism•Binding to other reseptors than target (loss, side effects)•Binding to target reseptor
Structure - Physiochemical properties• Acid / base properties• Water solubility• Partition coefficient• (Crystal structure)• Stereochemistry
A
BC
D
Drug
Biomolecular target
Desired responce
D
BC
A
No desired resonceSide effects??
![Page 19: Drug Design: Functional groups / Pharmacological Activity Structure ...](https://reader031.fdocuments.us/reader031/viewer/2022030319/584999d91a28aba93a915a85/html5/thumbnails/19.jpg)
Restricted rotation - optically active rotamers
P
P
(R)-(+)-BINAP
P
P
(S)-(-)-BINAP
I I
INH2
O
CO2H*
Chiral C-atom
Chiral axis (restrict. tot.)4 stereoisomers
X-ray contrast agent
![Page 20: Drug Design: Functional groups / Pharmacological Activity Structure ...](https://reader031.fdocuments.us/reader031/viewer/2022030319/584999d91a28aba93a915a85/html5/thumbnails/20.jpg)
•Screening/Design/Serendipity/Natural products •Lead compound•Structure Optimisation•Actual Drug
Refinement of lead structure:•Determining pharmacophore•Functional group modification
Pharmacophore: The part of the molecule that contains the functional groups that actually binds to the reseptor
Morfin
O
OHN
OH
N
O
O
Petidine
N
O
O
Dextropropoxyphene
![Page 21: Drug Design: Functional groups / Pharmacological Activity Structure ...](https://reader031.fdocuments.us/reader031/viewer/2022030319/584999d91a28aba93a915a85/html5/thumbnails/21.jpg)
N
N N
N
O
Cl
Lead compoundN
N N
NAr
XY
Z
Rel high activity
N
N N
N
O
R
R ≠ CH2Ph
N
N N
NR
R=H, alkyl
Inactive
N
N N
NAr
Pharmacophore??
Azapurines??
Deazapurines?? N
N N
Ar
R
??
N
NAr
??
Antimycobacterials
??
X
Ar
![Page 22: Drug Design: Functional groups / Pharmacological Activity Structure ...](https://reader031.fdocuments.us/reader031/viewer/2022030319/584999d91a28aba93a915a85/html5/thumbnails/22.jpg)
Improvement of lead by functional group modification
•Activity•Toxicity•Bioavailability•Metabolism
Isosters:Functional groups that results in approx. the same propertiesSteric and electronic similarities
S
bp 81 oC bp 84 oC
-CH=CH- and -S- are isosters
N
bp 116 oC
-C= and -N= not isosters
(at least with respect to bp)
![Page 23: Drug Design: Functional groups / Pharmacological Activity Structure ...](https://reader031.fdocuments.us/reader031/viewer/2022030319/584999d91a28aba93a915a85/html5/thumbnails/23.jpg)
Bioisosters:Functional groups that results in approx. the same biological properties
Classical bioisostersSteric and electronic similarities
Monovalent-F, -H-OH, -NH2-H, -F, -OH, -NH2, -CH3-SH, -OH-Cl, -Br, -CF3
Divalent-C=S, -C=O, -C=NH, -C=C-
Trivalente-CH=, -N=
Tetravalente
Rings
N S O
N C
![Page 24: Drug Design: Functional groups / Pharmacological Activity Structure ...](https://reader031.fdocuments.us/reader031/viewer/2022030319/584999d91a28aba93a915a85/html5/thumbnails/24.jpg)
N
N N
N
O
X
-X π σp % Inhib at6.25 µg/mL
MIC(µg/mL)
-H 0.00 0.00 >90 3.13-F 0.15 0.06 >90 6.25-Cl 0.70 0.23 >90 6.25-OH -0.61 -0.37 79 n.d.-OMe -0.04 -0.27 >90 1.56-NH2 -1.23 -0.66 23 n.d.-NMe2 0.18 -0.83 >90 12.5-CH3 0.60 -0.17 >90 3.13-t-Bu 1.98 -0.20 >90 12.5-SO2Me -1.63 0.72 23 n.d.Bioisosters
σ: electronic effects; σ>0 electron withdrawing, σ<0 electron donatingπ: Lipophilicity, π>0 increased lipophil. rel to H
Non-classical bioisostersNot strong steric or electronic similarities
N
N
NNHO
O
N
N
NN NHN
O
HO2C
Angiotensin II antagonists(Hypertention)
N
NH
pKa 14.2
NN
NH
pKa 9.2
NN
NH
pKa 10.3
NNN
NH
pKa 4.9 ≈ karboksylsyrer